incb059872
Small moleculeexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2016 (NCT02712905)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- LSD1/CoREST complexINHIBITOR
LSD1/CoREST complex inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- incb059872
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04061421 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2019 | Astex Pharmaceuticals, Inc., Incyte, Theradex, Vanderbilt University |
| NCT03514407 | Phase 1 | Jun 27, 2018 | Incyte |
| NCT03132324 | Phase 1 | Apr 27, 2017 | Incyte |
| NCT02712905 | Phase 1/Phase 2 (Phase 2) | May 1, 2016 | Incyte |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Incyte | For profit | 4 | 3 | 2 | 2016 |
| Astex Pharmaceuticals, Inc. | For profit | 1 | 0 | 1 | 2019 |
| Theradex | For profit | 1 | 0 | 1 | 2019 |
| Vanderbilt University | Academic/Hospital | 1 | 1 | 1 | 2019 |
4 organizations
Page 1 / 1